Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03654651 · ClinicalTrials.gov registry record · Phase 2
Peanuts and Glycemic Control
A Phase 2 study, sponsored by Penn State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03654651: Completed Phase 2 study, sponsored by Penn State University.
NCT03654651 is a Phase 2 study that has completed, run by Penn State University. The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03654651, a Phase 2 study, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
A two-period randomized crossover study will be conducted to determine the effect of peanuts on glycemic control, and elucidate the role of the microbiome in glucose regulation, in individuals with impaired fasting glucose.
Primary Outcome
Within-condition mean differences (change from baseline).
Interventions
- DRUG Peanut
- DRUG High carbohydrate snack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2019-12-20 |
| Phase | Phase 2 |
What the finished NCT03654651 record still lists
NCT03654651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Peanut is the first listed.
NCT03654651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03654651 about?
NCT03654651 is a clinical study titled "Peanuts and Glycemic Control". A two-period randomized crossover study will be conducted to determine the effect of peanuts on glycemic control, and elucidate the role of the microbiome in glucose regulation, in individuals with impaired fasting glucose.
What is the current status of trial NCT03654651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2018-10-01. Estimated completion is 2019-12-20.
What interventions are being tested in trial NCT03654651?
The interventions under investigation include: Peanut (DRUG), High carbohydrate snack (DRUG).
Who is sponsoring clinical trial NCT03654651?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03654651's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI